Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model

Neuropathology

Volumn 33, Issue 5, 2013, Pages 515-525

  Harter, Patrick N ^a   Dützmann, Stephan ^a   Drott, Ulrich ^a   Zachskorn, Cornelia ^a   Hattingen, Elke ^a   Capper, David ^b   Gessler, Florian ^a   Senft, Christian ^a   Seifert, Volker ^a   Plate, Karl H ^a   Kögel, Donat ^a   Mittelbronn, Michel ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Glioma; Invasion; Migration; P53; Tissue factor

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROTEIN P53; PROTEINASE ACTIVATED RECEPTOR 2; TF 9 10H 10; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CANCER MORPHOLOGY; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; GENE MUTATION; GENETIC ANALYSIS; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VIVO STUDY; INTRACRANIAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION;

GLIOMA; INVASION; MIGRATION; P53; TISSUE FACTOR;

ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL LINE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; RECEPTOR, PAR-2; THROMBOPLASTIN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884987114     PISSN: 09196544     EISSN: 14401789     Source Type: Journal    
DOI: 10.1111/neup.12018     Document Type: Article

References (39)

1. Ohgaki H, Dessen P, Jourde B etal. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
2. Farin A, Suzuki SO, Weiker M, Goldman JE, Bruce JN, Canoll P. Transplanted glioma cells migrate and proliferate on host brain vasculature: a dynamic analysis. Glia 2006; 53: 799-808.
3. Zagzag D, Esencay M, Mendez O etal. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer's structures. Am J Pathol 2008; 173: 545-560.
4. Scherer HJ. The forms of growth in gliomas and their practical significance. Brain 1940; 63: 1-35.
5. Brat DJ, Castellano-Sanchez AA, Hunter SB etal. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. Cancer Res 2004; 64: 920-927.
6. Noell S, Wolburg-Buchholz K, Mack AF etal. Dynamics of expression patterns of AQP4, dystroglycan, agrin and matrix metalloproteinases in human glioblastoma. Cell Tissue Res 2012; 347: 429-441.
7. Yamamoto M, Mohanam S, Sawaya R etal. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996; 56: 384-392.
8. Levin VA, Phuphanich S, Yung WKA etal. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006; 78: 295-302.
9. Wagner S, Stegen C, Bouterfa H etal. Expression of matrix metalloproteinases in human glioma cell lines in the presence of IL-10. J Neurooncol 1998; 40: 113-122.
10. Dützmann S, Gessler F, Harter PN etal. The pro-migratory and pro-invasive role of the procoagulant tissue factor in malignant gliomas. Cell Adh Migr 2010; 4: 515-522.
11. Gessler F, Voss V, Dützmann S, Seifert V, Gerlach R, Kögel D. Inhibition of tissue factor/protease-activated receptor-2 signaling limits proliferation, migration and invasion of malignant glioma cells. Neuroscience 2010; 165: 1312-1322.
12. Gessler F, Voss V, Seifert V, Gerlach R, Kögel D. Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci Lett 2011; 497: 49-54.
13. Belting M, Ahamed J, Ruf W. Signaling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 2005; 25: 1545-1550.
14. Josso F, Prou-Wartelle O. Interaction of tissue factor and factor VII at the earliest phase of coagulation. Thromb Diath Haemorrh Suppl 1965; 17: 35-44.
15. Hjortoe GM, Petersen LC, Albrektsen T etal. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood 2004; 103: 3029-3037.
16. Versteeg HH, Schaffner FF, Kerver MM etal. Inhibition of tissue factor signaling suppresses tumor growth. Blood 2007; 111: 190-199.
17. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: correlation with the malignant phenotype of human breast disease. Nat Med 1996; 2: 209-215.
18. Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nisi T, Ushio Y. Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer 1996; 77: 1877-1883.
19. Seto S, Onodera H, Kaido T etal. Tissue factor expression in human colorectal carcinoma: correlation with hepatic metastasis and impact on prognosis. Cancer 2000; 88: 295-301.
20. Yu JL, May L, Lhotak V etal. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105: 1734-1741.
21. Guan M, Jin J, Su B, Liu W, Lu Y. Tissue factor expression and angiogenesis in human glioma. Clin Biochem 2002; 35: 321-325.
22. Rong Y, Durden DL, Van Meir EG, Brat DJ. "Pseudopalisading" necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol 2006; 65: 529-539.
23. Rong Y, Hu F, Huang R, Mackman N etal. Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res 2006; 66: 7067-7074.
24. Rong Y, Post D, Pieper R, Durden D, Van Meir E, Brat D. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65: 1406-1413.
25. Svensson KJ, Kucharzewska P, Christianson HC etal. Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci U S A 2011; 108: 13147-13152.
26. CMA. [homepage on the Internet]. cma.nci.nih.gov. [cited 21 March 2012.] Available from URL: https://caintegrator.nci.nih.gov/caintegrator/studySummary.action
27. Home - TCGA [homepage on the Internet]. Cancergenome.nih.gov. [cited 20 December 2012.] Available from URL: http://cancergenome.nih.gov/
28. Demuth T, Hopf NJ, Kempski O etal. Migratory activity of human glioma cell lines in vitro assessed by continuous single cell observation. Clin Exp Metastasis 2000; 18: 589-597.
29. Hetschko H, Voss V, Horn S, Seifert V, Prehn JHM, Kögel D. Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma. J Neurooncol 2008; 86: 265-272.
30. Weller M, Felsberg J, Hartmann C etal. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009; 27: 5743-5750.
31. Mittelbronn M, Platten M, Zeiner P etal. Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 2011; 122: 353-365.
32. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52 (11): 2745-2756.
33. Muruganandam A, Herx LM, Monette R, Durkin JP, Stanimirovic DB. Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood-brain barrier. FASEB J 1997; 11: 1187-1197.
34. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010; 37: 48-57.
35. Sahm F, Capper D, Jeibmann A etal. Addressing diffuse glioma as a systemic brain disease with single-cell analysis. Arch Neurol 2012; 69: 523-526.
36. Bogdahn U, Hau P, Stockhammer G etal. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011; 13: 132-142.
37. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997; 3: 1362-1368.
38. Dorfleutner A, Hintermann E, Tarui T, Takada Y, Ruf W. Cross-talk of integrin alpha 3 beta 1 and tissue factor in cell migration. Mol Biol Cell 2004; 15: 4416-4425.
39. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin Thromb Hemost 2006; 32: 24-32.